Biomedical subjects
D C McLeod
Publications and source records attributed to D C McLeod.
Origins of the Annals of Pharmacotherapy and a tribute to its founder.
Explore the source record for details and available documents.
Pharmacotherapy. Part III. A process of certification.
Explore the source record for details and available documents.
Pharmacotherapy. Part IV. The future of specialization and certification in pharmacy.
Explore the source record for details and available documents.
Loratadine: a nonsedating antihistamine with once-daily dosing.
Loratadine is an addition to the class of nonsedating antihistamines which includes terfenadine, astemizole, and acrivastine. Loratadine is chemically related to the tricyclic antidepressants. Animal data have shown that insignificant amounts of loratadine enter the brain, and it has a threefold greater affinity for peripheral as compared with central histamine 1-receptors. Loratadine has one main metabolite, descarbethoxyloratadine, which is four times more active than the parent drug. Loratadine reaches peak plasma concentration in 1-2 hours; the metabolite does so in 3-4 hours. Their respective elimination half-lives are about 10 and 20 hours. Onset of action is within 1 hour and duration is at least 24 hours. Once-daily dosing is recommended. Generally, loratadine is as efficacious as existing antihistamines in relieving symptoms of allergic rhinitis, urticaria, and in suppressing wheal formation. Reports of sedation and other adverse reactions are no more frequent than found with placebo. Tachyphylaxis has not been noted in humans, and there is minimal potential for drug interactions based on animal data. Loratadine and terfenadine have comparable therapeutic applications. Both have shown minimal adverse effects, but loratadine has a quicker onset and longer duration of action. These two agents are useful for acute allergic reactions. In contrast, astemizole has an onset of action of several days and is most useful for prophylactic treatment of seasonal allergies.
Let us not tarry: ACCP past and future.
Explore the source record for details and available documents.
Pharmacotherapy. Part I. A new pharmacy specialty.
Explore the source record for details and available documents.
Pharmacotherapy. Part II. Administering the certification process.
Explore the source record for details and available documents.
Pharmaceutical marketing--rewriting the textbook.
Explore the source record for details and available documents.
An analgesic for nonprescription pain reliever promotions.
Explore the source record for details and available documents.
Therapeutic drug interchange: the battle heats up.
Explore the source record for details and available documents.
A very persistent dilemma.
Explore the source record for details and available documents.
SI units in drug therapeutics.
Explore the source record for details and available documents.
Specialization in clinical pharmacy: update 1987.
Explore the source record for details and available documents.
Contrast in pharmacy manpower planning between the United States and northern European countries.
Explore the source record for details and available documents.
Residency training: pharmacy's rate-limiting step to clinical competency.
Explore the source record for details and available documents.
Therapeutic drug monitoring as a standard of care.
Explore the source record for details and available documents.
Pharmaceutical services at Sint Radboud Hospital.
This article describes a contemporary pharmaceutical and clinical pharmacy program at a major university medical center in The Netherlands. The service components described illustrate practice concepts on an international basis. The number of professional personnel and their training vary considerably among the nations, and this requires imagination in adapting practice concepts in various countries. Several types of technical persons are used to support the professional role of the pharmacist at Sint Radboud Hospital. Pharmaceutical research and international liaison are high priorities in the department of clinical pharmacy. Primary differences at Sint Radboud, as compared with U.S. hospitals, are the use of various supportive personnel and a continuing drug analysis/quality control program for commercial pharmaceuticals.